⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4078483 | 1.00 | — | — | |
| SCHEMBL209161 | 1.00 | — | — | |
| SCHEMBL2198175 | 1.00 | — | — | |
| SCHEMBL2193904 | 1.00 | — | — | |
| SCHEMBL4563322 | 0.91 | — | — | |
| SCHEMBL4563324 | 0.91 | — | — | |
| SCHEMBL3134477 | 0.89 | — | — | |
| SCHEMBL3134430 | 0.89 | — | — | |
| SCHEMBL1408601 | 0.88 | — | — | |
| SCHEMBL4087414 | 0.88 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9193752-B2 | 5′-substituted bicyclic nucleosides and oligomeric compounds prepared therefrom | ISIS PHARMACEUTICALS, INC. (US) | 2015-11-24 | — | — | US | disclosed |
| EP-2376516-B1 | BIS-MODIFIED BICYCLIC NUCLEIC ACID ANALOGS | ISIS PHARMACEUTICALS INC (US) | 2013-04-17 | — | — | EP | disclosed |
| US-20130041144-A1 | 5'-SUBSTITUTED BICYCLIC NUCLEOSIDES AND OLIGOMERIC COMPOUNDS PREPARED THEREFROM | ISIS PHARMACEUTICALS, INC. (US) | 2013-02-14 | — | — | US | disclosed |
| US-8268980-B2 | 5′-modified bicyclic nucleic acid analogs | ISIS PHARMACEUTICALS, INC. (US) | 2012-09-18 | — | — | US | disclosed |
| EP-2066684-B1 | 5'-MODIFIED BICYCLIC NUCLEIC ACID ANALOGS | ISIS PHARMACEUTICALS INC (US) | 2012-07-18 | — | — | EP | disclosed |
| US-20120010393-A1 | 5'-MODIFIED BICYCLIC NUCLEIC ACID ANALOGS | ISIS PHARMACEUTICALS, INC. (US) | 2012-01-12 | — | — | US | disclosed |
| US-8088746-B2 | Bis-modified bicyclic nucleic acid analogs | ISIS PHARMACEUTICALS, INC. (US) | 2012-01-03 | — | — | US | disclosed |
| US-8030467-B2 | 5′-modified bicyclic nucleic acid analogs | ISIS PHARMACEUTICALS, INC. (US) | 2011-10-04 | — | — | US | disclosed |
| US-20100184966-A1 | 5'-MODIFIED BICYCLIC NUCLEIC ACID ANALOGS | ISIS PHARMACEUTICALS, INC. (US) | 2010-07-22 | — | — | US | disclosed |
| US-7750131-B2 | 5′-modified bicyclic nucleic acid analogs | ISIS PHARMACEUTICALS, INC. (US) | 2010-07-06 | — | — | US | disclosed |
| US-20100121045-A1 | BIS-MODIFIED BICYCLIC NUCLEIC ACID ANALOGS | IONIS PHARMACEUTICALS, INC. | 2010-05-13 | — | — | US | disclosed |
| US-7666854-B2 | Bis-modified bicyclic nucleic acid analogs | ISIS PHARMACEUTICALS, INC. (US) | 2010-02-23 | — | — | US | disclosed |
| US-20090192302-A1 | 5'-MODIFIED BICYCLIC NUCLEIC ACID ANALOGS | ISIS PHARMACEUTICALS, INC. (US) | 2009-07-30 | — | — | US | disclosed |
| US-20090156792-A1 | BIS-MODIFIED BICYCLIC NUCLEIC ACID ANALOGS | IONIS PHARMACEUTICALS, INC. | 2009-06-18 | — | — | US | disclosed |
| US-7547684-B2 | 5′-modified bicyclic nucleic acid analogs | ISIS PHARMACEUTICALS, INC. (US) | 2009-06-16 | — | — | US | disclosed |
| US-20070287831-A1 | 5'-MODIFIED BICYCLIC NUCLEIC ACID ANALOGS | ISIS PHARMACEUTICALS, INC | 2007-12-13 | — | — | US | disclosed |